Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Should You Buy?

Posted by Stanley Muller on Jul 18th, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) shares gapped up prior to trading on Thursday . The stock had previously closed at $19.24, but opened at $20.14. Ascentage Pharma Group International shares last traded at $20.2150, with a volume of 651 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 target price on the stock. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research restated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, June 15th. Finally, B. Riley Financial initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $46.43.

Get Our Latest Research Report on Ascentage Pharma Group International

Ascentage Pharma Group International Stock Performance

The stock’s 50-day moving average is $18.76 and its two-hundred day moving average is $22.67. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Hedge Funds Weigh In On Ascentage Pharma Group International

Institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG lifted its holdings in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000. Finally, Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth $383,000.

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.